Mechanistic Insights Into the Link Between Inflammation and Cardiovascular Disease

Liao, Katherine P.; Solomon, Daniel H.

doi:10.1161/circimaging.114.002235

Cited by 7 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These changes might be further worsened by some treatments as glucocorticoids. Furthermore, it has been described that the in ammatory and immunologic milieu of this type of diseases may exert proatherogenic effects at the endothelial and metabolic levels (11,12).…”

Section: Introductionmentioning

confidence: 99%

TNF inhibitors exert a “hidden” beneficial effect in the cardiovascular lipoprotein profile of RA patients

Calvo‐Alén

Lavin

Aurrecoechea

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: Higher cardiovascular risk has been largely described in rheumatoid arthritis as well as different effects of biologic agents in theses patients. The aim of present study is to analyze the effects of tumor necrosis factor inhibitors (TNFi) in the lipoprotein profile of rheumatoid arthritis (RA) patients using a broad laboratory assessment including a large number of no routine testsMETHODS: RA patients treated with and without TNFi were cross-sectionally compared regarding a broad spectrum of lipoprotein tests including serum levels of cholesterol, triglycerides, HDL, LDL and VLDL cholesterol, lipoprotein A (LpA), apolipoprotein A1 (Apo A) and B100 (Apo B), HDL, LDL and VLDL proteins, triglycerides and phospholipids, HDL Apo A, LDL and VLDL Apo B and paraoxonase 1 (PON 1), HDL, LDL and VLDL masses and number of particles of LDL and VLDL. Univariate and multivariate analyses of the different variables were performedRESULTS: Patients on treatment with TNFi showed a trend to be younger and had a longer disease duration. Regarding to the lipoprotein analyses, borderline significant higher levels of serum Apo A were detected and an independent association with lower HDL mass, LDL triglyceride, VLDL cholesterol, VLDL Apo B, VLDL mass, number of VLDL cholesterol molecules and number of particles of VLDL was clearly observed.CONCLUSIONS: TNFi treatment was associated with beneficial atherogenic effects at the lipoprotein level especially centered in VLDL related parameters consistent with a reduction of the remnant atherogenic risk.

show abstract

Section: Introductionmentioning

confidence: 99%

TNF inhibitors exert a “hidden” beneficial effect in the cardiovascular lipoprotein profile of RA patients

Calvo‐Alén

Lavin

Aurrecoechea

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The potential links between long-term inflammation and co-morbidities such as the development of dysplasia and cancer [ 4 , 5 ], microbial infection [ 6 ] and cardiovascular disease [ 7 ] have been well described. In this regard there have been reports of increases in systemic markers of inflammation during stable phases of BE in adult patients [ 8 ], and BE has been shown to be an independent risk factor for atherosclerosis [ 9 ] cardiovascular disease, which is 1.3 times more common in Indigenous people, and osteoporosis, which is 1.8 times more common in Indigenous males than their non-Indigenous counterparts [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Increased Peripheral Blood Pro-Inflammatory/Cytotoxic Lymphocytes in Children with Bronchiectasis

et al. 2015

View full text Add to dashboard Cite

ObjectiveBronchiectasis (BE) in children is common in some communities including Indigenous children in Australia. Relatively little is known about the nature of systemic inflammation in these children, especially the contribution of specific pro-inflammatory and cytotoxic lymphocyte subsets: T-cells, natural killer (NK) cells and NKT-like cells. We have shown that these cells produce increased cytotoxic (granzyme b and perforin) and inflammatory (IFNγ and TNFα) mediators in several adult chronic lung diseases and hypothesised that similar changes would be evident in children with BE.MethodsIntracellular cytotoxic mediators perforin and granzyme b and pro-inflammatory cytokines were measured in T cell subsets, NKT-like and NK cells from blood and bronchoalveolar samples from 12 children with BE and 10 aged-matched control children using flow cytometry.ResultsThere was a significant increase in the percentage of CD8+ T cells and T and NKT-like subsets expressing perforin/granzyme and IFNγ and TNFα in blood in BE compared with controls. There was a further increase in the percentage of pro-inflammatory cytotoxic T cells in Indigenous compared with non-Indigenous children. There was no change in any of these mediators in BAL.ConclusionsChildhood bronchiectasis is associated with increased systemic pro-inflammatory/cytotoxic lymphocytes in the peripheral blood. Future studies need to examine the extent to which elevated levels of pro-inflammatory cytotoxic cells predict future co-morbidities.

show abstract

“…Furthermore, it has been described that the inflammatory and immunologic milieu of this type of disease may exert pro-atherogenic effects at the endothelial and metabolic levels. 11,12 Specifically, it has been reported that a systemic inflammatory status may have a negative influence on the lipid profile of these patients that can be evident even before the clinical onset of the disease, as has been already underscored. Moreover, in RA as in other immunologically mediated systemic diseases such as systemic lupus erythematosus (SLE), it has been demonstrated that high-density lipoprotein (HDL) loses its protective characteristics against atherogenesis turning out into a pro-atherogenic phenotype.…”

Section: Introductionmentioning

confidence: 82%

“…Furthermore, it has been described that the inflammatory and immunologic milieu of this type of disease may exert pro-atherogenic effects at the endothelial and metabolic levels. 11 , 12 …”

Section: Introductionmentioning

confidence: 99%

TNF Inhibitors Exert a “Hidden” Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients

Calvo‐Alén¹,

Lavin²,

Aurrecoechea³

et al. 2022

BTT

View full text Add to dashboard Cite

Purpose A high cardiovascular risk has been described in patients with rheumatoid arthritis (RA); the effects of different biological agents have also been described in these patients. The aim of the present study is to examine the effects of tumor necrosis factor inhibitors (TNFi) in the lipoprotein profile of RA patients using a broad laboratory assessment including a large number of non-routine tests. Patients and Methods RA patients treated with and without TNFi (70 patients in each group) were cross-sectionally compared regarding a broad spectrum of lipoprotein parameters including serum levels of total and HDL, LDL and VLDL cholesterol triglycerides, lipoprotein A (LpA), apolipoprotein A1 (Apo A), B100 (Apo B) and paroxonase. For each lipoprotein subfraction (HDL, LDL and VLDL), we assess specific concentrations of cholesterol, triglycerides, phospholipids and proteins and total mass of each one. Additionally, HDL Apo A, LDL and VLDL Apo B concentrations and number of particles of LDL and VLDL were also determined. Exploratory univariate and multivariate analyses of the different variables were performed. Results Seventy patients in each subset were enrolled. Patients on treatment with TNFi showed a trend to be younger and to have a longer disease duration. Regarding the lipoprotein analyses, borderline significant higher levels of serum Apo A were detected and an independent association with lower HDL mass, LDL triglyceride, VLDL cholesterol, VLDL Apo B, VLDL mass, number of VLDL cholesterol molecules and number of particles of VLDL was clearly observed. Conclusion TNFi treatment was associated with beneficial atherogenic effects at the lipoprotein level especially centered in the VLDL-related parameters consistent with a reduction of the atherogenic risk.

show abstract

Mechanistic Insights Into the Link Between Inflammation and Cardiovascular Disease

Cited by 7 publications

References 20 publications

TNF inhibitors exert a “hidden” beneficial effect in the cardiovascular lipoprotein profile of RA patients

TNF inhibitors exert a “hidden” beneficial effect in the cardiovascular lipoprotein profile of RA patients

Increased Peripheral Blood Pro-Inflammatory/Cytotoxic Lymphocytes in Children with Bronchiectasis

TNF Inhibitors Exert a “Hidden” Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients

Contact Info

Product

Resources

About